• GBC announces appointment of new COO

      GBC announces appointment of new COO

        Geneva, Switzerland, October 2018. Following the recent successful financing of GBC-R1, a new molecule to treat allergic diseases (see also gbc-hpvac.com), and to support its other ongoing projects, the GBC is pleased to announce that Silvia H...

    • GBC-HpVac obtains seed financing

      GBC-HpVac obtains seed financing

      Geneva, Switzerland, October 2018. GBC-HpVac SA has successfully concluded a seed financing round, which enables it to proceed with the lead validation phase of its molecule GBC-R1. The production of new batches of GBC-R1 started in early October at ...

Go Top